REG - Vulcan Two Group PLC - Notice of AGM and Posting of Annual Report

Vulcan TwoAnnouncement

27/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260527:nRSa7754Fa&default-theme=true

RNS Number : 7754F  Vulcan Two Group PLC  27 May 2026

27 May 2026

 Vulcan Two Group plc

(the "Company" or "Vulcan Two")

 

Notice of Annual General Meeting and Posting of Annual Report

 

Vulcan Two Group plc, the company aiming to create the UK's leading regulated
ePharmacy through buy and build, announces that the Company's Annual General
Meeting ("AGM") will be held at 2:00pm on Wednesday, 24 June 2026 at Canaccord
Genuity Limited, 88 Wood Street, London, EC2V 7QR.

 

The Annual Report and Accounts for the year ended 31 December 2025, together
with the Notice of Annual General Meeting, have been made available to
shareholders on the company's website at www.vulcantwo.com/investors
(http://www.vulcantwo.com/investors)

 

The Notice of the AGM, Annual Report, and Form of Proxy have been mailed to
shareholders who have elected to receive hard copies.

 

 

For further information please contact:

 

 Vulcan Two Group plc                                      Email: info@vulcantwo.com (mailto:info@vulcantwo.com)

 Michael Kraftman, Chief Executive Officer

 Keith Butcher, Chief Financial Officer

 Brendan O'Brien, Chief Operating Officer
 Canaccord Genuity Limited                                 Tel: +44 (0) 20 7523 8000

(Nominated Adviser and Sole Broker)

 Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott
 Alma Strategic Communications                             Email: vulcantwo@almastrategic.com (mailto:vulcantwo@almastrategic.com)

(Financial PR)

                                                         Tel: +44 (0) 20 3405 0205
 Justine James / Sam Modlin / Will Merison

 

Notes to Editors

Vulcan Two Group plc (AIM:VUL) is creating the UK's leading regulated
ePharmacy platform, through its disciplined buy-and-build strategy. Following
the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has
established a diversified, profitable platform spanning B2B prescription
fulfilment and B2C digital pharmacy services, with a high proportion of
recurring revenues and strong cash generation. Future growth is expected to be
supported through the acquisition of complementary businesses, expansion into
new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare,
eCommerce and buy-and-build expertise.

For more information, visit www.vulcantwo.com (http://www.vulcantwo.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAAKABPOBKDDPB



            Copyright 2019 Regulatory News Service, all rights reserved